WPV01

DRUG2 trials

Sponsors

Westlake Pharmaceuticals (Hangzhou) Co., Ltd.

Conditions

COVID-19 InfectionMild to Moderate COVID-19

Phase 2

Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 Infection

CompletedNCT05752175

Westlake Pharmaceuticals (Hangzhou) Co., Ltd.COVID-19 Infection

Start: 2023-03-10End: 2023-07-03Updated: 2024-06-12

Phase 3

Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19

CompletedNCT06197217

Westlake Pharmaceuticals (Hangzhou) Co., Ltd.Mild to Moderate COVID-19

Start: 2023-06-14End: 2023-09-20Updated: 2024-06-12

Related Papers

Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04.

2024-04-0916 citations